SOP Guide for Pharma

Capsule: SOP for Developing Capsule Fill Formulations – V 2.0

Capsule: SOP for Developing Capsule Fill Formulations – V 2.0

Standard Operating Procedure for Developing Capsule Fill Formulations

Department Capsule Manufacturing
SOP No. SOP/CM/023/2025
Supersedes SOP/CM/023/2022
Page No. Page 1 of 7
Issue Date 01/02/2025
Effective Date 05/02/2025
Review Date 01/02/2026

1. Purpose

The purpose of this SOP is to outline the procedure for developing capsule fill formulations, ensuring that the formulations meet regulatory, quality, and performance standards for safe and effective use.

2. Scope

This SOP applies to the development of all capsule fill formulations in the manufacturing process, including the selection of excipients, optimization of formulation components, and testing for bioavailability and stability.

3. Responsibilities

4. Accountability

The Formulation Development Supervisor is accountable for ensuring the proper development of capsule fill formulations, while the QA Manager ensures that the formulations meet all quality and regulatory standards.

5. Procedure

5.1 Selecting Active Pharmaceutical Ingredient (API) for Capsule Fill

Ensure the correct API is selected for the capsule fill formulation:

  1. API Characteristics
    1. Review the physicochemical properties of the API such as solubility, stability, and bioavailability to ensure its suitability for capsule fill formulations.
    2. Evaluate the API’s stability under various conditions, including temperature, humidity, and light, to ensure it will remain effective throughout the shelf life of the product.
  2. API Compatibility
    1. Conduct compatibility studies between the selected API and excipients to ensure there are no interactions that might affect the stability or efficacy of the capsule.
    2. Use methods such as DSC, FTIR, or HPLC to identify potential incompatibilities between the API and excipients.

5.2 Selecting Excipients for Capsule Fill

Choose suitable excipients for the formulation based on the properties of the API:

  1. Excipients Functionality
    1. Choose excipients such as fillers, binders, disintegrants, and lubricants that will support the API’s solubility, stability, and controlled release.
    2. Select excipients that comply with pharmacopoeial standards and are compatible with the API.
  2. Excipients Compatibility
    1. Conduct compatibility testing for each excipient with the API to identify any chemical, physical, or functional incompatibilities.
    2. Use techniques like FTIR and HPLC to confirm the stability and compatibility of the excipients in the formulation.

5.3 Optimizing the Fill Formulation

Optimize the capsule fill formulation to achieve the desired quality attributes:

  1. Formulation Development
    1. Mix the selected API with excipients to form a homogenous powder blend suitable for capsule filling.
    2. Adjust the amount of each excipient to achieve the desired capsule weight, dissolution rate, and stability.
  2. Granulation Process
    1. If necessary, granulate the powder blend to improve its flowability and compressibility, ensuring a uniform fill in the capsule.
    2. Use wet or dry granulation methods depending on the characteristics of the powder blend and desired end product.
  3. Powder Flow and Compressibility Testing
    1. Test the flow properties of the powder blend using bulk density, tapped density, and angle of repose to ensure consistent filling during capsule manufacturing.
    2. Test the compressibility of the powder blend if needed, using standard methods such as tablet hardness tests to assess its ability to form uniform capsules.

5.4 Capsule Fill Testing and Evaluation

Evaluate the capsule fill for various performance parameters:

  1. Weight Uniformity
    1. Ensure the uniformity of capsule fill by measuring the weight of individual capsules and calculating the average weight and standard deviation.
    2. Ensure that the weight variation is within acceptable limits as per regulatory guidelines.
  2. Content Uniformity
    1. Perform content uniformity tests to ensure the correct dosage of API in each capsule.
    2. Verify that the API content in each capsule falls within the specified range of the label claim.
  3. Dissolution Testing
    1. Conduct dissolution tests on the capsule formulation to ensure that the API is released effectively and at the desired rate.
    2. Monitor the dissolution profile to confirm that it meets the required bioavailability specifications.

5.5 Stability Testing of Capsule Fill Formulation

Conduct stability studies to ensure the capsule fill formulation remains effective and stable over time:

  1. Accelerated Stability Testing
    1. Subject the capsule formulation to accelerated stability testing under conditions of high temperature and humidity to predict its shelf life.
    2. Evaluate the physical, chemical, and microbiological properties of the formulation to determine its stability and any degradation over time.
  2. Long-Term Stability Testing
    1. Conduct long-term stability studies to monitor the capsule formulation under normal storage conditions for an extended period.
    2. Analyze any changes in the appearance, dissolution, and potency of the formulation to confirm its stability over time.

5.6 Documentation and Record-Keeping

Ensure proper documentation of all formulation development activities:

  1. Formulation Development Report
    1. Compile a detailed report of the formulation development process, including excipient selection, formulation parameters, testing results, and stability data.
    2. Ensure that all documentation is signed off by the formulation development team and reviewed by the QA team.
  2. Record Retention
    1. Ensure that all records related to the capsule fill formulation, including testing and stability data, are securely stored and easily accessible for future reference and regulatory submissions.

6. Abbreviations

7. Documents

  1. Formulation Development Report (Annexure-1)
  2. Stability Testing Data (Annexure-2)
  3. Capsule Fill Testing Report (Annexure-3)

8. References

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Formulation Development Report

Date Formulation Name API Excipient Outcome
02/02/2025 Capsule A API-123 Excip-456 Stable formulation

Annexure-2: Stability Testing Data

Date Test Type Result Action Taken
02/02/2025 Accelerated Stability No degradation observed Proceed with further testing

Annexure-3: Capsule Fill Testing Report

Date Test Type Result Action Taken
02/02/2025 Weight Uniformity Pass Continue formulation optimization

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial Version New SOP Creation QA Head
01/02/2025 2.0 Updated formulation development process Standardization QA Head
Exit mobile version